Comparative tolerability of drug therapies used to treat incontinence and enuresis

Drug Safety

Volumn 19, Issue 2, 1998, Pages 123-139

  Owens, R Gregory ^a   Karram, Mickey M ^a  

^a GOOD SAMARITAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM ANTAGONIST; CHOLINERGIC RECEPTOR BLOCKING AGENT; DESMOPRESSIN; DICYCLOVERINE; DOXEPIN; ESTROGEN; FLAVOXATE; FLUNARIZINE; FLURBIPROFEN; IMIPRAMINE; MUSCLE RELAXANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NOREPHEDRINE; OXYBUTYNIN; PHENYLPROPANOLAMINE; PROPANTHELINE BROMIDE; SCOPOLAMINE; TERODILINE; TOLTERODINE; TRICYCLIC ANTIDEPRESSANT AGENT; TROSPIUM CHLORIDE;

ABDOMINAL PAIN; ANTICHOLINERGIC EFFECT; ARTICLE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DISEASE SEVERITY; DOSE CALCULATION; DRUG EFFICACY; DRUG TOLERABILITY; ENURESIS; FATIGUE; HEADACHE; HEART ARRHYTHMIA; HUMAN; ILEUS; INCONTINENCE; INTRANASAL DRUG ADMINISTRATION; MOUTH ULCER; MUSCLE ATONIA; NAUSEA; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; SLEEP DISORDER; STRESS INCONTINENCE; SYNCOPE; TREATMENT OUTCOME; URGE INCONTINENCE; URINE RETENTION; VOMITING; XEROSTOMIA;

EID: 0031814243     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199819020-00004     Document Type: Article

References (62)

1. International Continence Society Committee on Standardisation of Terminology. The standardisation of terminology of lower urinary tract function. Scand J Urol Nephrol 1988; Suppl. 114: 5-19
2. Urinary Incontinence in Adults Guideline Update Panel. Urinary incontinence in adults: acute and chronic management. US Dept Health Human Serv AHCPR 1996; 2: 1-51
3. Meyhoff HH, Gerstenberg TC, Nordling J. Placebo - the drug of choice in female motor incontinence? Br J Urol 1983: 55: 34-7
4. Zorzitto ML, Jewett MAS, Fernie GR, et al. Effectiveness of propantheline bromide in the treatment of geriatric patients with detrusor instability. Neurourol Urodyn 1986; 5: 133-40
5. Holmes DM, Montz FJ, Stanton SL. Oxybutinin versus propantheline in the management of detrusor instability: a patient-regulated variable dose trial. Br J Obstet Gynaecol 1989; 96:607-12
6. Thuroff JW, Bunke B, Ebner A, et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol 1991; 145: 813-7
7. Coombes GM, Millard RJ. Urinary urge incontinence: randomised crossover trials of penthienate versus placebo and propantheline. Med J Aust 1996; 165: 473-6
8. Muskat Y, Bukovsky I, Shneider D, et al. The use of scopolamine in the treatment of detrusor instability. J Urol 1996; 156: 1989-90
9. Tapp AJS, Cardozo LD, Versi E, et al. The treatment of detrusor instability in postmenopausal women with oxybutynin chloride: a double blind placebo controlled study. Br J Obstet Gynaecol 1990; 97: 521-6
10. Moore EH, Hay DM, Imrie AE, et al. Oxybutynin hydrochloride (3mg) in the treatment of women with idiopathic detrusor instability. J Urol 1990; 66: 479-85
11. Nilsson CG, Lukkari E, Haarala M, et al. Comparison of a 10 mg controlled release oxybutynin tablet with a 5 mg oxybutynin tablet in urge incontinence patients. Neurourol Urodyn 1997; 16: 533-42
12. Enzelsberger H, Helmer H, Kurtz CH. Intravesical instillation of oxybutynin in women with idiopathic detrusor instability: a randomized trial. Br J Obstet Gynaecol 1995; 102: 929-30
13. Stohrer M, Bauer P, Giannetti BM, et al. Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries: a multicentre placebo-controlled double-blind trial. Urol Int 1991; 47: 138-43
14. Madersbcher H, Stohrer M, Richter R, et al. Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyperreflexia. Br J Urol 1995; 75:452-6
15. Jonas U, Hofner K, Madersbacher H, et al. Efficacy and safety of two doses of tolterodine vs placebo in patients with detrusor overactivity and symptoms of frequency urge incontinence, and urgency: urodynamic evaluation. World J Urol 1997; 15: 144-51
16. Castleden CM, Duffin HM, Gulati RS. Double-blind study of imipramine and placebo for incontinence due to bladder instability: Age Ageing 1986; 15: 299-303
17. Lose G, Jorgensen L, Thunedborg P. Doxepin in the treatment of female detrusor overactivity: a randomized double-blind crossover study. J Urol 1989; 142: 1024-6
18. Cardozo L, Stanton SL, Robinson H, et al. Evaluation of flurbiprofen in detrusor instability. BMJ 1980; 2: 281-2
19. Palmer JH, Worth PHL, Exton-Smith AN. Flunarizine: a once-daily therapy for urinary incontinence. Lancet 1981; 8: 279-81
20. Lehtonen T, Rannikko S, Lindell O, et al. The effect of phenylpropanolamine on female stress urinary incontinence. Ann Chir Gynaecol 1986; 75: 236-41
21. Collste L, Lindskog M. Phenylpropanolamine in treatment of female stress urinary incontinence. Double-blind placebo controlled study in 24 patients. Urology 1987; 30 (4): 398-403
22. Fossberg E, Beisland HO, Lundgren RA. Stress incontinence in females: treatment with phenylpropanolamine. Urol Int 1983; 38: 293-9
23. Ek A, Andersson KE, Gullberg B, et al. The effects of long-term treatment with norephedrine on stress incontinence and urethral closure pressure profile. Scand J Urol Nephrol 1978; 12: 105-10
24. Walter S, Wolf H, Barlebo H, et al. Urinary incontinence in postmenopausal women treated with estrogen. A double-blind clinical trial. Urol Int 1978; 33: 135-43
25. Samsioe G, Jansson I, Mellstrom D, et al. Occurrence, nature and treatment of urinary incontinence in a 70-year-old female population. Maturitas 1985; 7: 335-42
26. Cardozo L, Rekers H, Tapp A, et al. Oestriol in the treatment of postmenopausal urgency: a multicentre study. Maturitas 1993; 18: 47-53
27. Wilson PD, Faragher B, Butler B, et al. Treatment with oral piperazine oestrone sulphate for genuine stress incontinence in postmenopausal women. Br J Obstet Gynaecol 1987; 94: 568-74
28. Walter S, Kjaergaard B, Andersen JT, et al. Stress urinary incontinence in postmenopausal women treated with oral estrogen (estriol) and an alpha-adrenoceptor-stimulating agent (phenylpropanolamine): a randomized double-blind placebo controlled study. Int Urogynecol J 1990; 1: 74-9
29. Hilton P, Tweddell AL, Mayne C. Oral and intravaginal estrogens alone and in combination with alpha-adrenergic stimulation in genuine stress incontinence. Int Urogynecol J 1990; 1: 80-6
30. Drutz HP. Neurophysiology and neuropharmacology of the lower urinary tract. Int Urogynecol J 1990; 1: 91-9
31. Miller K, Atkin B, Moody ML. Drug therapy for nocturnal enuresis. Drugs 1992; 44: 47-56
32. Benson GS, Sarshik SA, Raezer DM, et al. Comparative effects and mechanisms of action of atropine, propantheline, flavoxate, and imipramine. Urology 1997; IX: 31-5
33. Wall LL. Diagnosis and management of urinary incontinence due to detrusor instability. Obstet Gynecol Surv 1990; 45 (11 Suppl.): 1S-47S
34. Andersson KE. Current concepts in the treatment of disorders of micturition. Drugs 1988; 35: 477-94
35. Langtry HD, McTavish D, Terodiline: a review of its pharmacological properties, and therapeutic use in the treatment of urinary incontinence. Drugs 1990; 40(5): 748-61
36. Norton P, Karram M, Wall LW, et al. Randomized double-blind trial of terodiline in the treatment of urge incontinence in women. Obstet Gynecol 1994; 84: 386-91
37. Yarker YE, Goa KL, Fitton A. Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in detrusor instability. Drugs Aging 1995; 6 (3): 243-62
38. Waldeck K, Larsson B, Andersson KE. Comparison of oxybutynin and its active metabolite N-desethyl-oxybutynin in the human detrusor and parotid gland. J Urol 1997; 157: 1093-7
39. Stahl MMS, Ekstrom B, Mattiasson A, et al. Urodynamic and other effects of terodiline: a novel antimuscarinic drug for the treatment of detrusor overactivity Neurourol Urodyn 1995; 14: 647-55
40. Nilvebrant L, Hallen B, Larsson G. Terodoline - a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci 1997; 60(13/14): 1129-36
41. Castleden CM, Duffin HM, Millar AW. Dicyclomine hydrochloride in detrusor instability - a controlled clinical pilot study. J Clin Exp Ger 1987; 9 (4): 265-70
42. Ruffmann R. A review of flavoxate hydrochloride in the treatment of urge incontinence. J Int Med Res 1988; 16: 317-30
43. Levin RM, Staskin DR, Wein AJ. Analysis of anticholinergic and musculotropic effects of desmethylimipramine on the rabbit urinary bladder. Urol Res 1983; 11: 259-63
44. Goodman and Gilman's, The pharmacological basis of therapeutics. 8th ed. New York: Permagon Press, 1990
45. Pinder RM, Brogden RN, Speight TM, et al. Doxepin up-to-date: a review of its pharmacological properties and therapeutic efficacy with particular reference to depression. Drugs 1977; 13: 161-218
46. Hassouna M, Nishizawa O, Miyagawa I, et al. Role of calcium ion antagonists of the bladder detrusor muscle: in vitro and in vivo study. J Urol 1986; 135(6): 1327-31
47. Amark P, Beck O. Effect of phenylpropanolamine on incontinence in children with neurogenic bladders. A double-blind crossover study. Acta Paediatr 1992; 81: 345-50
48. Fantl JA, Cardozo L, McClish D, et al. Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis. First report of the hormones and urogenital therapy committee. Obstet Gynecol 1994 Jan; 83: 12-8
49. Moffat ME. Nocturnal enuresis: a review of the efficacy of treatments and practical advice for clinicians. J Dev Behav Pediatr 1997 Feb; 18(1):49-56
50. Robson WL, Leung AKC. Side effects and complication of treatment with desmopressin for enuresis. J Natl Med Assoc 1994; 86(10): 775-8
51. Hjalmas K, Bengtsson B. Efficacy, safety, and dosing of desmopressin for nocturnal enuresis in Europe. Clin Pediatr 1993; special ed: 19-24
52. Fjellestad-Paulsen A, Wille S, Harris S. Comparison of intranasal and oral desmopressin for nocturnal enuresis. Arch Dis Child 1987; 62: 674-7
53. Stenberg A, Lackgren G. Desmopressin tablets in the treatment of severe nocturnal enuresis in adolescents. Pedeatrics 1994; 94(6): 841-6
54. Janknegt RA, Zweers HMM, Delaere KPJ, et al. Oral desmopressin as a new treatment modality for primary nocturnal enuresis in adolescents and adults: A double-blind, randomized, multicenter study. J Urol 1997; 157: 513-7
55. Rushton HG. Nocturnal enuresis: epidemiology, evaluation and currently available treatment options. J Pediatr 1989; 114: 691-6
56. Fritz GR, Rockney RM, Yeung AS. Plasma levels and efficacy of imipramine treatment for enuresis. J Am Acad Child Adolesc Psychiatry 1994; 33 (1): 60-4
57. Blackwell B, Currah J. The psychopharmacology of nocturnal enuresis. In: Kolvin I, Mackeith RC, Meadow SR, editors. Bladder control and enuresis. London: Heinemann Medical. 1973: 231-57
58. Smellie JM, MeGrigor VS, Meadow SR, et al. Nocturnal enuresis: a placebo controlled trial of two antidepressant drugs. Arch Dis Child 1996; 75: 62-6
59. Milner G, Hills NF. A double-blind assessment of antidepressants in the treatment of 212 enuretic patients. Med J Aust 1968; 943-7
60. Lovering JS, Tallett SE, McKendry JBJ. Oxybutynin efficacy in the treatment of primary enuresis. Pediatrics 1988; 82 (1): 104-6
61. Al-Waili NSD. Indomethacin suppository to treat primary nocturnal enuresis: double-blind study. J Urol 1989; 142: 1290-2
62. Al-Waili NSD. Diclofenac sodium in the treatment of primary nocturnal enuresis: double-blind crossover study. Clin Exp Pharmacol Physiol 1986; 13: 139-41